Stock Ratings / Health Care / KYNB / insiders

COCP (42) PBM (61) AKTX (36) MCRB (54) ⌘ Pro Terminal →

Kyntra Bio Inc. (KYNB) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

Q: Are KYNB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies KYNB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

$4.65 -1.48% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Kyntra Bio Inc. (KYNB) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE D • SELL / AVOID Cap $18.8M

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERSELL / AVOID • D

2-of-3 JEV AI Jury Bearish Warning

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E · Rk C

Each axis scored 0–20

12M PRICE TARGET CONE-6.2% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for KYNB)Realized 20D OHLCV Swing Band: ±12.5%

SEC FORM 4 × 13F HEDGE FUNDS × CONGRESSIONAL STOCK ACT

KYNB Smart-Money Thermometer: NET EXECUTIVE TRIMMING / PROFIT-TAKING

Explore All 13F & Congress Whales →

▲ Disclosed Buys: 0 ($0)▼ Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (KYNB)

No recent open-market Form 4 cluster sales or emergency dumps flagged on KYNB. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring KYNB)

✓Walkthrough of KYNB's RQD Radar, SEC cash-conversion gap & downside invalidation levels
✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

KYNB // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -36.04%📐 HORIZONTAL RANGE

2026-10-30O $4.54H $4.70L $4.48C $4.65VOL 24.4K

RES: $9.15SUP: $4.20SMA50: $6.68SMA200: $7.10

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

KYNB Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 KYNB Butterfly Map → + Track KYNB →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

8.0%/yr Implied 5Y Growth

vs. -65.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on KYNB today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for KYNB. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for KYNB today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (KYNB)

Health Care Rank #521 of 1016 ⚔️ COCP vs KYNB Full Matrix →

1. Head-to-Head Health Care Peer Comparison (KYNB vs. COCP, PBM, AKTX, MCRB)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, Kyntra Bio Inc. (KYNB) ranks #521 by composite RQD confidence (44/100, grade D) and #839 by equity capitalization ($18.8M). Within this direct 5-issuer industry benchmark cohort, KYNB leads on earnings valuation at N/A trailing P/E, while KYNB leads on capital efficiency and profitability with -35.0% ROIC and 91.4% gross margin. PBM currently holds the highest overall quantitative score in the immediate peer group at 61/100 (C-) compared with KYNB at 44/100 (D).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
KYNB ACTIVE Kyntra Bio Inc.	D	44/100	—	91.4%	-35.0%	-1.48%	$18.8M	Benchmark Subject
COCP Cocrystal Pharma Inc.	D-	42/100	—	—	-35.0%	-1.01%	$18.9M	/cocp-vs-kynb →
PBM Psyence Biomedical Ltd.	C-	61/100	—	—	—	+6.18%	$19.2M	/pbm-vs-kynb →
AKTX Akari Therapeutics plc ADS	D-	36/100	—	—	-35.0%	-13.04%	$18.3M	/aktx-vs-kynb →
MCRB Seres Therapeutics Inc.	D+	54/100	—	—	-35.0%	+8.94%	$19.6M	/mcrb-vs-kynb →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000921299

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Kyntra Bio Inc. (KYNB) reported GAAP revenue of $6.4M (-78.3% vs. FY2024 revenue of $29.6M , and -86.2% cumulative change since FY2023) , GAAP net income of $183.5M, operating cash flow of -$4.8M, and free cash flow of -$4.8M (+96.5% YoY). On the balance sheet, KYNB closed FY2025 with $119.6M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$6.4M	$183.5M	-$4.8M	-$4.8M	$119.6M	—
FY2024 (FY)	2024-12-31	$29.6M	-$47.6M	-$138.0M	-$138.3M	$214.5M	—
FY2023 (FY)	2023-12-31	$46.8M	-$284.2M	-$315.0M	-$315.0M	—	—

3. KYNB Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is KYNB stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Kyntra Bio Inc. (NASDAQ: KYNB) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $4.65 (-1.48% 1D, market cap $18.8M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 8/20, Executive Insider Alignment 12/20, FRED Macro Regime Fit 13/20, and SEC Balance-Sheet Forensics 7/20. Across 1016 tracked Health Care issuers, KYNB ranks #521 in composite RQD confidence.

How does KYNB compare to COCP and PBM in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), KYNB carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of 91.4%, and ROIC of -35.0%. By comparison, COCP (Cocrystal Pharma Inc.) holds a D- grade (42/100 RQD, P/E N/A, ROIC -35.0%, cap $18.9M) and PBM (Psyence Biomedical Ltd.) posts a C- grade (61/100 RQD, P/E N/A, ROIC —, cap $19.2M). Among the 5-stock peer group, KYNB leads on earnings multiple (N/A) while KYNB leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for KYNB?

Per KYNB's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000921299), Kyntra Bio Inc. generated $6.4M in revenue (-78.3% YoY), $183.5M in net income, and -$4.8M in free cash flow against $119.6M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is KYNB trading relative to its 50-day, 200-day, and 52-week technical levels?

KYNB last traded at $4.65 (-1.48% on volume of 25,378 shares), positioning the stock -30.39% below its 50-day simple moving average ($6.68) and -34.51% below its 200-day simple moving average ($7.10). Across its 52-week range of $4.32 to $11.39, KYNB sits at the 4.7% percentile with a 14-day RSI of 26.9 (OVERSOLD (<32)) and an implied next-earnings move of ±12.5% ($4.07 to $5.23).

KYNB Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

Are KYNB insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies KYNB leadership and institutional positioning as: NET EXECUTIVE TRIMMING / PROFIT-TAKING.

Direct Sub-Reports: KYNB RQD Cockpit KYNB 12M Forecast KYNB Earnings & Move KYNB Dividends & DRIP KYNB Insiders & 13F KYNB Whale Options KYNB Profit Sankey KYNB News & Why